ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… of CEP290-associated inherited retinal disease called Leber congenital amaurosis (LCA10): A randomized, … in a Ph1b/2 INSIGHT extension trial in CEP290-associated Leber congenital amaurosis (LCA10) Presenter: Dr. Stephen R. … oligonucleotide, for the treatment of CEP290-associated Leber congenital amaurosis (LCA10): a randomized, …
… in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) Presenter: … Date: May 6, 2021 at 5:15pm EDT About Leber Congenital Amaurosis 10 (LCA10) Leber congenital …
Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
